BridgeMD
New treatment option for Lung Cancer
Official title Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
ClinicalTrials.gov ID: NCT06776588
What this study is testing
- What it's testing
- This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age ≤ 75 years;
- GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm;
- Refusing radical surgery or being unable to tolerate surgical treatment;
- Normal coagulation function, platelet count ≥ 60 × 109 /L;
- ECOG score ≤ 2 points;
You likely can't join if
- Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm
- Platelets \<50×109 /L
- Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term
- Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension
- Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation
- Patients with severe heart, liver, kidney and brain dysfunction
See the full eligibility criteria
- Age ≤ 75 years;
- GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm;
- Refusing radical surgery or being unable to tolerate surgical treatment;
- Normal coagulation function, platelet count ≥ 60 × 109 /L;
- ECOG score ≤ 2 points;
- Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm
- Platelets \<50×109 /L
- Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term
- Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension
- Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation
- Patients with severe heart, liver, kidney and brain dysfunction
- Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term
- Patients with an estimated survival period of less than 6 months
The study team makes the final eligibility decision.
Where it's taking place
- Harbin, Heilongjiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Harbin, Heilongjiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.